{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:09:08Z","timestamp":1793138948258,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["(No. 30970886"],"award-info":[{"award-number":["(No. 30970886"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Project of Dalian City","award":["No. 2008E13SF193"],"award-info":[{"award-number":["No. 2008E13SF193"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Portal hypertension (PH) is the main cause of complications and death in liver cirrhosis. The effect of oral administration of octreotide (OCT), a drug that reduces PH by the constriction of mesenteric arteries, is limited by a remarkable intestinal first-pass elimination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The bile duct ligation (BDL) was used in rats to induce liver cirrhosis with PH to examine the kinetics and molecular factors such as P-glycoprotein (P-gp), multidrug resistance-associated protein 2 (MRP2) and cytochrome P450 3A4 (CYP3A4) influencing the intestinal OCT absorption via in situ and in vitro experiments on jejunal segments, transportation experiments on Caco-2 cells and experiments using intestinal microsomes and recombinant human CYP3A4. Moreover, RT-PCR, western blot, and immunohistochemistry were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both in situ and in vitro experiments in jejunal segments showed that intestinal OCT absorption in both control and PH rats was largely controlled by P-gp and, to a lesser extent, by MRP2. OCT transport mediated by P-gp and MRP2 was demonstrated on Caco-2 cells. The results of RT-PCR, western blot, and immunohistochemistry suggested that impaired OCT absorption in PH was in part due to the jejunal upregulation of these two transporters. The use of intestinal microsomes and recombinant human CYP3A4 revealed that CYP3A4 metabolized OCT, and its upregulation in PH likely contributed to impaired drug absorption.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Inhibition of P-gp, MRP2, and CYP3A4 might represent a valid option for decreasing intestinal first-pass effects on orally administered OCT, thereby increasing its bioavailability to alleviate PH in patients with cirrhosis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12876-020-01532-4","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T17:13:16Z","timestamp":1609953196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiaoyu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunxiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-4959","authenticated-orcid":false,"given":"Zhijun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoucheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"issue":"1","key":"1532_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3350\/cmh.2017.0064","volume":"24","author":"YS Seo","year":"2018","unstructured":"Seo YS. Prevention and management of gastroesophageal varices. Clin Mol Hepatol. 2018;24(1):20\u201342.","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"1532_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis R. Baveno VI Faculty: expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743\u201352.","journal-title":"J Hepatol"},{"issue":"1","key":"1532_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11894-006-0058-9","volume":"8","author":"DC Rockey","year":"2006","unstructured":"Rockey DC. Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices. Curr Gastroenterol Rep. 2006;8(1):7\u201313.","journal-title":"Curr Gastroenterol Rep"},{"key":"1532_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1046\/j.1365-2036.2003.01682.x","volume":"18","author":"P Schiedermaier","year":"2003","unstructured":"Schiedermaier P, Koch L, Stoffel-Wanger B, Layer G, Sauerberuch T. Effect of proparnolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis. Aliment Pharmacol Ther. 2003;18:777\u201384.","journal-title":"Aliment Pharmacol Ther"},{"key":"1532_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/hep.1840060119","volume":"6","author":"G Garcia-Tsao","year":"1986","unstructured":"Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, Morse SS, Alberts JL. Short-term effects of propranolol on portal venous pressure. Hepatology. 1986;6:101\u20136.","journal-title":"Hepatology"},{"key":"1532_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.phrs.2005.08.005","volume":"53","author":"H Wang","year":"2006","unstructured":"Wang H, Liao ZX, Chen M, Hu XL. Effects of hepatic fibrosis on ofloxacin pharmacokinetics. Pharmacol Res. 2006;53:28\u201334.","journal-title":"Pharmacol Res"},{"key":"1532_CR7","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1124\/dmd.107.016170","volume":"35","author":"SN Barnes","year":"2007","unstructured":"Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken MJ, Jakowski AB, Pruimboom-Brees IM, Cherrington NJ, Manautou JE. Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Meta Dispos. 2007;35:1963\u20139.","journal-title":"Drug Meta Dispos"},{"key":"1532_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0168-8278(03)00096-5","volume":"38","author":"G Zollner","year":"2003","unstructured":"Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol. 2003;38:717\u201327.","journal-title":"J Hepatol"},{"key":"1532_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00424-007-0235-1","volume":"454","author":"C Kneuer","year":"2007","unstructured":"Kneuer C, Honscha W, G\u00e4bel G, Honscha KU. Adaptive response to increased bile acids: induction of MDR1 gene expression and P-glycoprotein activity in renal epithelial cells. Pflugers Arch. 2007;454:587\u201394.","journal-title":"Pflugers Arch"},{"key":"1532_CR10","first-page":"124","volume":"67","author":"YA Cho","year":"2012","unstructured":"Cho YA, Lee W, Choi JS. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Pharmazie. 2012;67:124\u201330.","journal-title":"Pharmazie"},{"key":"1532_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40262-012-0030-9","volume":"52","author":"F Scaglione","year":"2013","unstructured":"Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52:69\u201382.","journal-title":"Clin Pharmacokinet"},{"key":"1532_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0168-8278(03)00410-0","volume":"39","author":"H Kojima","year":"2003","unstructured":"Kojima H, Nies AT, K\u00f6nig J, Hagmann W, Spring H, Uemura M, Fukui H, Keppler D. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol. 2003;39:693\u2013702.","journal-title":"J Hepatol"},{"key":"1532_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1386-6346(01)00159-0","volume":"23","author":"GA Kullak-Ublick","year":"2002","unstructured":"Kullak-Ublick GA, Baretton GB, Oswald M, Renner EL, Paumgartner G, Beuers U. Expression of the hepatocyte canalicular multidrug resistance protein(MRP2) in primary biliary cirrhosis. Hepatol Res. 2002;23:78\u201382.","journal-title":"Hepatol Res"},{"key":"1532_CR14","first-page":"157","volume":"1","author":"ES Eldesoky","year":"2007","unstructured":"Eldesoky ES, Kamel SI, Farghaly AM, Bakheet MY, Hedaya MA, Siest JP. Study of the urinary ratio of 6 beta-hydroxycortisol\/ cortisol as a biomarker of CYP3A4 activity in Egyptian patients with chronic liver diseases. Biomark Insights. 2007;1:157\u201364.","journal-title":"Biomark Insights"},{"key":"1532_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01718.x","volume":"55","author":"R Orlando","year":"2003","unstructured":"Orlando R, Piccoli P, De Martin S, Padrini R. Palatini P\u202f: Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003;55:86\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"1532_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/jhep.2001.22646","volume":"33","author":"G Zollner","year":"2001","unstructured":"Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K, Trauner M. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001;33:633\u201346.","journal-title":"Hepatology"},{"key":"1532_CR17","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147\u201361.","journal-title":"Eur J Clin Pharmacol"},{"key":"1532_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11010-012-1232-z","volume":"364","author":"R Ghosh","year":"2012","unstructured":"Ghosh R. D, Chakraborty P, Banerjee K, Adhikary A, Sarkar A, Chatterjee M, Das T, Choudhuri SK: The molecular interaction of a copper chelate with human P-glycoprotein. Mol Cell Biochem. 2012;364:309\u201320.","journal-title":"Mol Cell Biochem"},{"key":"1532_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/jpet.113.203562","volume":"345","author":"L Gu","year":"2013","unstructured":"Gu L, Chen J, Synold TW, Forman BM, Kane SE. Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice. J Pharmacol Exp Ther. 2013;345:438\u2013845.","journal-title":"J Pharmacol Exp Ther"},{"key":"1532_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.taap.2012.08.032","volume":"265","author":"W Liu","year":"2012","unstructured":"Liu W, Feng Q, Li Y, Ye L, Hu M, Liu Z. Coupling of UDP- glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin. Toxicol Appl Pharmacol. 2012;265:316\u201324.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1532_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/sj.bjp.0703003","volume":"129","author":"H Gutmann","year":"2000","unstructured":"Gutmann H, Miller DS, Droulle A, Drewe J, Fahr A, Fricker G. P-glycoprotein- and mrp2- mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000;129:251\u20136.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1532_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/0016-5085(81)90014-7","volume":"80","author":"J Bosch","year":"1981","unstructured":"Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology. 1981;80(3):518\u201325.","journal-title":"Gastroenterology"},{"key":"1532_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1530\/eje.0.1460701","volume":"146","author":"SW Lamberts","year":"2002","unstructured":"Lamberts SW, van der Lely AJ, Hofland LJ. New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol. 2002;146:701\u20135.","journal-title":"Eur J Endocrinol"},{"key":"1532_CR24","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.5897\/AJB10.1776","volume":"9","author":"Z Zhai","year":"2010","unstructured":"Zhai Z. Octreotide decreases portal pressure: Hepatic stellate cells may play a pivotal role. Afr J Biotechnol. 2010;9:1833\u20138.","journal-title":"Afr J Biotechnol"},{"issue":"1","key":"1532_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00005176-200401000-00011","volume":"38","author":"Y Eroglu","year":"2004","unstructured":"Eroglu Y, Emerick KM, Whitington PF, Alonso EM. Octreotide therapy for control of acute gastrointestinal bleeding in children. J Pediatr Gastroenterol Nutr. 2004;38(1):41\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"9","key":"1532_CR26","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/j.1572-0241.2007.01481.x","volume":"102","author":"G Garcia-Tsao","year":"2007","unstructured":"Garcia-Tsao G, Sanyal AJ, Grace ND, Carey WD. Prevention and management of gasroesophageal varices and varicel hemorrhage. Am J Gastroenterol. 2007;102(9):2086\u2013102.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1532_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.gie.2005.07.031","volume":"62","author":"W Qureshi","year":"2005","unstructured":"Qureshi W, Adler DG, Davila R, Egan J, Hirota W, Leighton J, Rajan E, Zuckerman MJ, Fanelli R, Wheeler-Harbaugh J, Baron TH, Faigel DO. Standards of Practice Committee: ASGE Guideline: the role of endoscopy in the management of variceal hemorrhage, updated July 2005. Gastrointest Endosc. 2005;62(5):651\u20135.","journal-title":"Gastrointest Endosc"},{"issue":"8","key":"1532_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1365-2036.2012.05050.x","volume":"35","author":"N Chandok","year":"2012","unstructured":"Chandok N, Kamath PS, Blei A, Bosch J, Carey W, Grace N, Kowdley KV, Benner K, Groszmann RJ. Randomised Clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension. Aliment Pharmacol Ther. 2012a;35(8):904\u201312.","journal-title":"Aliment Pharmacol Ther"},{"key":"1532_CR29","doi-asserted-by":"crossref","unstructured":"Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis . Hepatology. 2007; 46(3): 922\u2013938.","DOI":"10.1002\/hep.21907"},{"issue":"11","key":"1532_CR30","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/j.1365-2036.2012.05088.x","volume":"35","author":"M Wells","year":"2012","unstructured":"Wells M, Chande N, Adams P, Beaton M, Levstik M, Boyce E, Mrkobrada M. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther. 2012;35(11):1267\u201378.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1532_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11901-014-0221-y","volume":"13","author":"B Fortune","year":"2014","unstructured":"Fortune B, Garcia-Tsao G. Current management strategies for acute esophageal variceal hemorrhage. Curr Hepatol Rep. 2014;13(1):35\u201342.","journal-title":"Curr Hepatol Rep"},{"key":"1532_CR32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/j.1572-0241.2007.01262.x","volume":"102","author":"L Spahr","year":"2007","unstructured":"Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A. A 3-month course of long-acting repeatable Octreotide (Sandostatin LAR) improves portal hypertension inpatients with cirrhosis: a randomized controlled study. Am J Gastroenterol. 2007;102:1397\u2013405.","journal-title":"Am J Gastroenterol"},{"key":"1532_CR33","unstructured":"US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001. https:\/\/www.fda.gov\/CVM. Accessed 20 May 2001."},{"key":"1532_CR34","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/1520-6017(200007)89:7<951::AID-JPS13>3.0.CO;2-1","volume":"89","author":"M Thanou","year":"2000","unstructured":"Thanou M, Verhoef JC, Marbach P, Junginger HE. Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci. 2000;89:951\u20137.","journal-title":"J Pharm Sci"},{"key":"1532_CR35","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1210\/jc.2012-1179","volume":"97","author":"S Tuvia","year":"2012","unstructured":"Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Bidlingmaier M, Strasburger CJ, Kleinberg DL, Melmed S, Mamluk R. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab. 2012;97:2363\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1532_CR36","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1210\/jc.2014-4113","volume":"100","author":"S Melmed","year":"2015","unstructured":"Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015;100:1699\u2013708.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1532_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1517\/14740330903379525","volume":"8","author":"J Bornschein","year":"2009","unstructured":"Bornschein J, Drozdov I, Malfertheiner P. Octreotide LAR: safety and tolerability issues. Expert Opin Drug Saf. 2009;8(6):755\u201368.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1532_CR38","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1378\/chest.13-0382","volume":"144","author":"MM Chan","year":"2013","unstructured":"Chan MM, Chan MM, Mengshol JA, Fish DN, Chan ED. Octreotide: a drug often used in the critical care setting but not well understood. Chest. 2013;144(6):1937\u201345.","journal-title":"Chest"},{"issue":"8","key":"1532_CR39","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1365-2036.2012.05050.x","volume":"35","author":"N Chandok","year":"2012","unstructured":"Chandok N, Kamath PS, Blei A, Bosch J, Carey W, Grace N, Kowdley KV, Benner K, Groszmann RJ. Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension. Aliment Pharmacol Ther. 2012b;35(8):904\u201312.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"1532_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4321\/S1130-01082007000800006","volume":"99","author":"J Molina Infante","year":"2007","unstructured":"Molina Infante J, P\u00e9rez Gallardo B, Fern\u00e1ndez BM. Update on medical therapy for obscure gastrointestinal hemorrhage. Rev Esp Enferm Dig. 2007;99(8):457\u201362.","journal-title":"Rev Esp Enferm Dig"},{"key":"1532_CR41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2165\/00003495-199753040-00009","volume":"53","author":"JC Gillis","year":"1997","unstructured":"Gillis JC, Noble S, Goa KL. Octreotide long-acting release(LAR) A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drug. 1997;53:681\u201399.","journal-title":"Drug"},{"key":"1532_CR42","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/sj.bjp.0704557","volume":"135","author":"G Fricker","year":"2002","unstructured":"Fricker G, Nobmann S, Miller DS. Permeability of porcine blood brain barrier to somatostatin analogues. Br J Pharmacol. 2002;135:1308\u201314.","journal-title":"Br J Pharmacol"},{"key":"1532_CR43","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/aps.2009.142","volume":"30","author":"HM Fang","year":"2009","unstructured":"Fang HM, Xu JM, Mei Q, Diao L, Chen ML, Jin J, Xu XH. Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. Acta Pharmacol Sin. 2009;30:1566\u201372.","journal-title":"Acta Pharmacol Sin"},{"key":"1532_CR44","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2133\/dmpk.DMPK-11-RG-014","volume":"26","author":"Q Miao","year":"2011","unstructured":"Miao Q, Liu Q, Wang CY, Meng Q, Guo XJ, Peng JY. Inhibitory effect of zinc on the absorption of JBP485 via the gastrointestinal oligopeptide transporter (PEPT1) in rats. Drug Metab Pharmacokinet. 2011;26:494\u2013502.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1532_CR45","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1124\/dmd.110.032060","volume":"38","author":"J Zhang","year":"2010","unstructured":"Zhang J, Wang C, Liu Q, Meng Q, Cang J, Sun H, Gao Y, Kaku T, Liu K. Pharmacokinetic interaction between JBP485 and cephalexin in rats. Drug Metab Dispos. 2010;38:930\u20138.","journal-title":"Drug Metab Dispos"},{"key":"1532_CR46","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3748\/wjg.v17.i3.322","volume":"17","author":"SB Guo","year":"2011","unstructured":"Guo SB, Duan ZJ, Li Q, Sun XY. Effect of heme oxygenase-1 on renal function in rats with liver cirrhosis. World J Gastroenterol. 2011;17:322\u20138.","journal-title":"World J Gastroenterol"},{"key":"1532_CR47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1476-5381.1993.tb12799.x","volume":"108","author":"J Drewe","year":"1993","unstructured":"Drewe J, Fricker G, Vonderscher J, Beglinger C. Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether. Br J Pharmacol. 1993;108:298\u2013303.","journal-title":"Br J Pharmacol"},{"key":"1532_CR48","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2133\/dmpk.DMPK-11-RG-014","volume":"26","author":"Q Miao","year":"2011","unstructured":"Miao Q, Liu Q, Wang C, Meng Q, Guo X, Peng J, Kaku T, Liu K. Inhibitory effect of zinc on the absorption of JBP485 via the gastrointestinal oligopeptide transporter (PEPT1) in rats. Drug Metab Pharmacokinet. 2011;26:494\u2013502.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1532_CR49","first-page":"233","volume":"188","author":"S Tavelin","year":"2002","unstructured":"Tavelin S, Gr\u00e5sj\u00f6 J, Taipalensuu J, Ocklind G, Artursson P. Applications of epithelial cell culture in studies of drug transport. Methods Mol Biol. 2002;188:233\u201372.","journal-title":"Methods Mol Biol"},{"key":"1532_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/jpet.108.149815","volume":"330","author":"J Fan","year":"2009","unstructured":"Fan J, Liu S, Du Y, Morrison J, Shipman R, Pang KS. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha, 25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. J Pharmacol Exp Ther. 2009;330:389\u2013402.","journal-title":"J Pharmacol Exp Ther"},{"key":"1532_CR51","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1023\/A:1010951732288","volume":"18","author":"K Mohri","year":"2001","unstructured":"Mohri K, Uesawa Y. Enzymatic activities in the microsomes prepared from rat small intestinal epithelial cells by differential procedures. Pharm Res. 2001;18:1232\u20136.","journal-title":"Pharm Res"},{"key":"1532_CR52","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138\u201340.","journal-title":"Pathologe"},{"issue":"1","key":"1532_CR53","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/molecules19010686","volume":"19","author":"Y Chen","year":"2014","unstructured":"Chen Y, Wang Y, Zhou J, Gao X, Qu D, Liu C. Study on the mechanism of intestinal absorption of epimedins a, B and C in the Caco-2 cell model. Molecules. 2014;19(1):686\u201398.","journal-title":"Molecules"},{"issue":"2","key":"1532_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1124\/jpet.115.227546","volume":"355","author":"M Visentin","year":"2015","unstructured":"Visentin M, Stieger B, Merz M, Kullak-Ublick GA. Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2. J Pharmacol Exp Ther. 2015;355(2):145\u201351.","journal-title":"J Pharmacol Exp Ther"},{"key":"1532_CR55","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ejps.2008.08.004","volume":"35","author":"R Hayeshi","year":"2008","unstructured":"Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, Masungi C, Maubon N, Mols R, M\u00fcllertz A, M\u00f6nkk\u00f6nen J, O\u2019Driscoll C, Oppers-Tiemissen HM, Ragnarsson EG, Rooseboom M, Ungell AL. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci. 2008;35:383\u201396.","journal-title":"Eur J Pharm Sci"},{"key":"1532_CR56","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.7498\/aps.45.1160","volume":"45","author":"JJ Wang","year":"2010","unstructured":"Wang JJ, Liao XH, Ye M, Chen Y. In vitro absorption mechanism of strychnine and the transport interaction with liquiritin in Caco-2 cell monolayer model. Acta Pharm Sin. 2010;45:1160\u20134.","journal-title":"Acta Pharm Sin"},{"key":"1532_CR57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5650\/jos.61.35","volume":"61","author":"R Haigou","year":"2012","unstructured":"Haigou R, Miyazawa M. Metabolism of (+)-Terpinen-4-ol by Cytochrome P450 Enzyme in Human Liver Microsomes. J Oleo Sci. 2012;61:35\u201343.","journal-title":"J Oleo Sci"},{"key":"1532_CR58","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1248\/yakushi.129.601","volume":"129","author":"T Toda","year":"2009","unstructured":"Toda T, Ohi K, Kudo T, Yoshida T, Ikarashi N, Ito K, Sugiyama K. Antibiotics suppress Cyp3a in the mouse liver by reducing lithocholic acid- producing intestinal flora. Yakugaku Zasshi. 2009;129:601\u20138.","journal-title":"Yakugaku Zasshi"},{"key":"1532_CR59","first-page":"87","volume":"16","author":"AH Long","year":"2006","unstructured":"Long AH. Dynamic changes of cholestatic cirrhosis in rats and its significance. Chin J Integr Tradit Western Nephrol. 2006;16:87\u20139.","journal-title":"Chin J Integr Tradit Western Nephrol"},{"key":"1532_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.taap.2008.11.009","volume":"239","author":"IM Medina-D\u00edaz","year":"2009","unstructured":"Medina-D\u00edaz IM, Estrada-Mu\u00f1iz E, Reyes-Hern\u00e1ndez OD, Ram\u00edrez P, Vega L, Elizondo G. Arsenite and its metabolites, MMA(III) and DMA(III), modify CYP3A4, PXR and RXR alpha expression in the small intestine of CYP3A4 transgenic mice. Toxicol Appl Pharmacol. 2009;239:162\u20138.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1532_CR61","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1124\/jpet.111.188854","volume":"340","author":"L Li","year":"2012","unstructured":"Li L, Sinz M, Zimmermann K, Wang H. An IGF-1R inhibitor induces CYP3A4 expression through a PXR-independent, non-canonical CAR-related mechanism. J Pharmacol Exp Ther. 2012;340:688\u201397.","journal-title":"J Pharmacol Exp Ther"},{"key":"1532_CR62","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1517\/17425255.1.4.641","volume":"1","author":"U Christians","year":"2005","unstructured":"Christians U, Schmitz V, Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol. 2005;1:641\u201354.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"1532_CR63","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1159\/000447860","volume":"39","author":"JK Yan","year":"2016","unstructured":"Yan JK, Zhu J, Gu BL, Yan WH, Xiao YT, Zhou KJ, Wen J, Wang Y, Cai W. Soybean Oil-Based Lipid Emulsion Increases Intestinal Permeability of Lipopolysaccharide in Caco-2 Cells by Downregulation of P-Glycoprotein via ERK-FOXO 3a Pathway. Cell Physiol Biochem. 2016;39(4):1581\u201394.","journal-title":"Cell Physiol Biochem"},{"key":"1532_CR64","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ejps.2012.03.006","volume":"46","author":"XJ He","year":"2012","unstructured":"He XJ, Wang WR, Zhang Y. Yang Q\u202f: The effect of radixin knockdown on the expression and efflux function of MRP2 in SGC-7901 cells. Eur J Pharm Sci. 2012;46:426\u201334.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"1532_CR65","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1159\/000430379","volume":"37","author":"J Huang","year":"2015","unstructured":"Huang J, Zhao M, Li X, Ma L, Zhang J, Shi J, Li B, Fan W, Zhou Y. The Cytotoxic Effect of the Benzene Metabolite Hydroquinone is Mediated by the Modulation of MDR1 Expression via the NF-\u03baB Signaling Pathway. Cell Physiol Biochem. 2015;37(2):592\u2013602.","journal-title":"Cell Physiol Biochem"},{"key":"1532_CR66","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.phymed.2013.01.014","volume":"20","author":"TP Tran","year":"2013","unstructured":"Tran TP, Kim HG, Choi JH, Na MK, Jeong HG. Reversal of P-glycoprotein-mediated multidrug resistance is induced by mollugin in MCF-7\/adriamycin cells. Phytomedicine. 2013;20:622\u201331.","journal-title":"Phytomedicine"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-020-01532-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T20:03:48Z","timestamp":1670702628000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01532-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01532-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"13 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in strict accordance with the ethical standards of the International Council for Laboratory Animal Science. All animal experiments were conducted in accordance with the protocols approved by the Experimental Animal Ethical Committee of Dalian Medical University (No. L20180301).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}